The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

• Status: Recruiting
• Trial end date: 2023-05-02
• Target enrollment: 0
• Participant gender: All

Summary

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Singapore National Eye Centre
• Collaborator: National Medical Research Council (NMRC), Singapore
• Treatments: Atropine

Criteria

Inclusion criteria

1. One parent with myopia (<-3D in at least one eye)

2. SE +1.00D to -1.50D

3. Astigmatism < = 1.50D

4. Distance vision logMAR 0.2 or better in both eyes

5. Intraocular pressure of not greater than 21 mmHg

6. No allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride

Exclusion Criteria:

1. Any eye or systemic disease that affect vision or refractive error

2. Conditions where topical atropine contraindicated

3. Previous use of atropine or pirenzepine

4. Known past/current amblyopia or strabismus